Reference
·Primary source
Genome Thailand Cohort Size — 2026 Milestone
50,000 whole-genome and 200,000 array samples
Genome Thailand, the DMSc-coordinated national cohort programme, targets 50,000 whole-genome and 200,000 array samples by end-2026, recruited through Ramathibodi, Siriraj, Chulalongkorn, Khon Kaen, Chiang Mai, and provincial centres. The cohort delivers the first ethnic-Thai-calibrated variant database at clinical scale, materially improving CDx and PGx accuracy on Thai patients (Ashkenazi-, European-, and East-Asian-derived reference variants under-perform on ethnic Thai populations). NHSO bundle inclusion decisions and Thai FDA NGS CDx framework validation increasingly cite Genome Thailand evidence as the standard of reference; downstream lab and hospital operators integrate Genome Thailand variant frequencies into clinical reporting from 2026 onward.
Figure in context
Genome Thailand, the DMSc-coordinated national cohort programme, targets 50,000 whole-genome and 200,000 array samples by end-2026, recruited through Ramathibodi, Siriraj, Chulalongkorn, Khon Kaen, Chiang Mai, and provincial centres. The cohort delivers the first ethnic-Thai-calibrated variant database at clinical scale, materially improving CDx and PGx accuracy on Thai patients (Ashkenazi-, European-, and East-Asian-derived reference variants under-perform on ethnic Thai populations). NHSO bundle inclusion decisions and Thai FDA NGS CDx framework validation increasingly cite Genome Thailand evidence as the standard of reference; downstream lab and hospital operators integrate Genome Thailand variant frequencies into clinical reporting from 2026 onward.
Genome Thailand, the DMSc-coordinated national cohort programme, targets 50,000 whole-genome and 200,000 array samples by end-2026, recruited through Ramathibodi, Siriraj, Chulalongkorn, Khon Kaen, Chiang Mai, and provincial centres. The cohort delivers the first ethnic-Thai-calibrated variant database at clinical scale, materially improving CDx and PGx accuracy on Thai patients (Ashkenazi-, European-, and East-Asian-derived reference variants under-perform on ethnic Thai populations). NHSO bundle inclusion decisions and Thai FDA NGS CDx framework validation increasingly cite Genome Thailand evidence as the standard of reference; downstream lab and hospital operators integrate Genome Thailand variant frequencies into clinical reporting from 2026 onward.
Time scope
Milestone target 2026
Source basis
Primary source
Interpretation notes
What this tells you
Genome Thailand, the DMSc-coordinated national cohort programme, targets 50,000 whole-genome and 200,000 array samples by end-2026, recruited through Ramathibodi, Siriraj, Chulalongkorn, Khon Kaen, Chiang Mai, and provincial centres. The cohort delivers the first ethnic-Thai-calibrated variant database at clinical scale, materially improving CDx and PGx accuracy on Thai patients (Ashkenazi-, European-, and East-Asian-derived reference variants under-perform on ethnic Thai populations). NHSO bundle inclusion decisions and Thai FDA NGS CDx framework validation increasingly cite Genome Thailand evidence as the standard of reference; downstream lab and hospital operators integrate Genome Thailand variant frequencies into clinical reporting from 2026 onward.
What not to do with it
Use the linked report for interpretation and keep basis differences explicit.
Related figures
Adjacent numbers that add context without drowning the value.
Thailand Precision Medicine Market Size — 2027 Projection
NHSO NLEM planning documents, Thai FDA NGS CDx framework draft, lab operator filings, hospital programme disclosures, Insight Research triangulation
NHSO Priority CDx Panels Added to Oncology Bundles — FY2026-2027
NHSO National List of Essential Medicines planning documents, NHSO public consultations, hospital partner disclosures
Thailand Hospital-Integrated Personalised Cancer Package ASP
BDMS, Bumrungrad, BNH, Vejthani programme disclosures, Insight Research triangulation
Thailand Precision Medicine Test-Type Mix — 2026 Estimate
Lab operator filings, hospital programme disclosures, NHSO planning documents, Insight Research triangulation
Thailand Precision Medicine Operator Concentration — Top 6 Share
Operator disclosures, hospital programme websites, lab filings, Insight Research triangulation
Thailand Clinical NGS Oncology Panel Cost-of-Goods (50-gene panel)
Lab operator filings, Asia Genomics, Quantum Tech), reagent supplier benchmarks, Insight Research triangulation
Report context
Atlas actors in this figure's reports
Profiles covered in the report that cite this number.